Holen Sie sich die Stockscreener-App
34.61
1.58%
0.54
Handel nachbörslich:
34.80
0.19
+0.55%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TEVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$34.07
Offen:
$34.54
24-Stunden-Volumen:
4.44M
Relative Volume:
0.68
Marktkapitalisierung:
$40.30B
Einnahmen:
$17.53B
Nettoeinkommen (Verlust:
$1.58B
KGV:
25.72
EPS:
1.3457
Netto-Cashflow:
$444.18M
1W Leistung:
+1.58%
1M Leistung:
+12.96%
6M Leistung:
+31.50%
1J Leistung:
+104.07%
1-Tages-Spanne:
$34.16
$34.93
1-Wochen-Bereich:
$33.75
$34.93
52-Wochen-Spanne:
$14.99
$37.34
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Firmenname
Teva Pharmaceutical Industries Ltd Adr
Sektor
Telefon
972 (3) 914-8213
Adresse
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-12-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-05-28 | Eingeleitet | Truist | Buy |
| 2025-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Hochstufung | Argus | Hold → Buy |
| 2024-03-08 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-11-27 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-06 | Hochstufung | UBS | Sell → Neutral |
| 2023-05-25 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-06-14 | Fortgesetzt | UBS | Neutral |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Herabstufung | Argus | Buy → Hold |
| 2021-10-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Herabstufung | UBS | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Eingeleitet | Oppenheimer | Perform |
| 2020-08-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Fortgesetzt | Goldman | Neutral |
| 2020-06-01 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-24 | Fortgesetzt | Citigroup | Neutral |
| 2020-04-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-02-24 | Herabstufung | Edward Jones | Hold → Sell |
| 2019-11-12 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-07-05 | Hochstufung | Argus | Hold → Buy |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-06-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Herabstufung | UBS | Buy → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-07 | Fortgesetzt | UBS | Buy |
Alle ansehen
Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten
A Look At Teva (NYSE:TEVA) Valuation After EMA Accepts Filing For Monthly Schizophrenia Injection - Sahm
Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LSX:883035 - TradingView
TEVA Stock Price, Quote & Chart | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva Pharmaceutical’s SWOT analysis: stock navigates growth reset - Investing.com
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
TEVA Stock Chart | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After A Strong Year And Recent Pullback - Sahm
Earnings call transcript: Teva Q1 2026 earnings beat forecasts - Investing.com
Earnings call transcript: Teva Q1 2026 earnings beat forecasts By Investing.com - Investing.com Canada
How Investors May Respond To Teva (TEVA) Showcasing CNS Growth And Emalex Deal At Key Conferences - Sahm
Earnings call transcript: Teva beats Q1 2026 expectations with strong growth - Investing.com
Earnings call transcript: Teva beats Q1 2026 expectations with strong growth By Investing.com - Investing.com Australia
A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Q1 2026 And Biopharma Pipeline Progress - Sahm
Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its Strong Multi Year Rally? - Sahm
Reddit Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Why Teva (TEVA) Is Up 14.1% After Strong Q1 Profitability And Neuroscience Pivot News - Sahm
Teva Pharmaceutical (TEVA) Q1 EPS Of US$0.32 Tests Bullish Profitability Narrative - Sahm
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan - Sahm
Teva Pharmaceutical Indus Q1 2026 Earnings Call Transcript - Sahm
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets - Sahm
Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors - Sahm
Teva Enjoys Strong Start to 2026 Thanks to Strong Momentum in Branded Portfolio - Morningstar
Earnings call transcript: Teva beats Q1 2026 forecasts, stock surges 7.5% - Investing.com
Intel Upgraded, Toyota Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.
Is It Too Late To Reassess Teva (TEVA) After Its 118.5% One-Year Surge? - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch - Sahm
Teva- Pharmaceutical Industries Ltd.ADR (TEVA) News, Articles, Events & Latest Updates - Stocktwits
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners - Sahm
Teva Pharmaceutical (ADR) stock (US88162G1031): Why generic drug execution is suddenly worth a close - AD HOC NEWS
Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)? - Sahm
A Look At Teva Pharmaceutical Industries (TEVA) Valuation After Recent Biosimilar Regulatory Milestones - Sahm
Target Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones - Sahm
Assessing Teva Pharmaceutical Industries (TEVA) Valuation After New Biosimilar Approvals And Pipeline Progress - Sahm
Missile Strike Tests Teva Supply Resilience And Biosimilar Growth Plans - Sahm
Price to sales ratio of Teva Pharmaceutical Industries Limited Sponsored ADR – BSESOF:TEV - TradingView
Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential - Sahm
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Weakness - Sahm
Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LS:883035 - TradingView
Teva Releases Q1 2026 Aide Memoire - Sahm
Finanzdaten der Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.54%
1.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):